Evidence map›Paper›PMID 41483046›Full record

SynthesisObesity surgery2026

Recurrent Weight Gain after Weight Loss Induced by Lifestyle Intervention, Metabolic and Bariatric Surgery, or Semaglutide in Adults with Obesity: A Systematic Review of Randomized Controlled Trials.

Huixian Chen, Xiaojing Guo, Tianxue Long, Mingzi Li

Abstract readSystematic ReviewReview
PubMed Publisher
In one paragraph

Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huixian ChenSchool of Nursing, Peking University, Beijing, China.
Xiaojing GuoSchool of Nursing, Peking University, Beijing, China.
Tianxue LongSchool of Nursing, Peking University, Beijing, China.
Mingzi LiSchool of Nursing, Peking University, Beijing, China. limingzi@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity management is challenged by high rates of recurrent weight gain following initial loss. We systematically reviewed 29 randomized controlled trials comparing long-term outcomes of lifestyle interventions, semaglutide, and metabolic and bariatric surgery (MBS). Databases were searched to March 2025, and data were synthesized using pairwise and network meta-analysis. Lifestyle interventions ranked highest in preventing recurrent weight gain, while semaglutide may support sustained weight reduction during ongoing therapy but is followed by rebound after discontinuation. MBS demonstrated relatively sustained weight loss (> 10% maintained at 5-10 years), although RCT evidence was limited. These findings highlight the need for long-term, structured maintenance strategies and further high-quality trials with standardized outcomes.

Indexed as

Anti-Obesity AgentsBariatric SurgeryGlucagon-Like PeptidesObesityWeight GainWeight LossAdultHumansLife StyleRandomized Controlled Trials as TopicRecurrenceTreatment OutcomeAnti-Obesity AgentsGlucagon-Like PeptidesLifestyle interventionMetabolic and bariatric surgeryObesityRecurrent weight gainSemaglutideWeight cycling

Identifiers

PMID41483046

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.